Management of Axillary Lump with Hyperemia

Initial Clinical Assessment

• The American College of Radiology recommends performing axillary ultrasound as the initial imaging modality for a patient presenting with an axillary lump with hyperemia, to differentiate between infectious/inflammatory causes and malignancy 1, 2, 3
• The presence of hyperemia significantly narrows the differential diagnosis, with key considerations including infectious causes, inflammatory conditions, and malignancy with inflammatory features 4, 3
• The hyperemic presentation suggests an acute process requiring prompt evaluation to prevent progression and guide appropriate treatment 2, 3

Imaging Strategy

• The American College of Radiology recommends axillary ultrasound as the most appropriate initial imaging modality for any palpable axillary lump, including those with hyperemia 1, 2, 5, 6, 7
• Ultrasound allows assessment of whether the mass is solid or cystic, lymph node morphology, surrounding soft tissue inflammation, and vascular flow patterns 5, 6, 7, 8
• For patients ≥30 years of age, the National Comprehensive Cancer Network recommends diagnostic mammography and/or digital breast tomosynthesis to complement axillary ultrasound and evaluate for an occult breast primary lesion 3

Tissue Diagnosis

• The American College of Radiology recommends performing ultrasound-guided core needle biopsy rather than fine needle aspiration if the ultrasound demonstrates suspicious features or if clinical concern persists despite benign-appearing imaging 1, 5, 6, 7
• Core biopsy has a sensitivity of 88% and specificity of 98-100%, compared to FNA sensitivity of 74% and specificity of 98-100% 1, 5, 6
• Core biopsy provides architectural information crucial for distinguishing reactive lymphadenopathy from lymphoma and allows for immunohistochemical studies 1, 5

Management Based on Biopsy Results

• If benign/reactive lymphadenopathy is diagnosed, the National Comprehensive Cancer Network recommends treating the underlying infection or inflammatory condition appropriately and considering short-interval follow-up ultrasound to document resolution 3
• If malignancy of breast origin is diagnosed, the National Comprehensive Cancer Network recommends proceeding with breast MRI if mammography/ultrasound shows no breast primary and following NCCN Guidelines for Breast Cancer management 3
• If lymphoma is suspected, special pathologic evaluation and/or surgical excision may be required rather than core biopsy alone 3

Critical Pitfalls to Avoid

• The National Comprehensive Cancer Network warns against assuming hyperemia automatically indicates benign disease, as malignancy can present with overlying skin changes 3
• The American College of Radiology warns against relying on negative ultrasound alone to exclude malignancy, as axillary ultrasound has relatively low negative predictive value and sensitivity 1, 6, 7
• The American College of Radiology warns against performing mammography alone without ultrasound, as mammography has a high false-negative rate for detecting axillary lymphadenopathy 7
• The American College of Radiology warns against delaying biopsy if imaging shows suspicious features, as the absence of fatty hilum has 90-93% positive predictive value for malignancy 5, 6, 7, 8

Imaging and Biopsy Guidelines for Women with an Axillary Lump

Initial Imaging Strategy

• Axillary ultrasound should be the first‑line imaging test for any woman presenting with a palpable axillary lump, whether unilateral or bilateral. The American College of Radiology (ACR) cites multiple studies supporting this approach. 9
• Women aged ≥ 30 years: Perform diagnostic mammography (or digital breast tomosynthesis) together with axillary ultrasound in the same visit to search for an occult breast primary. The ACR recommends this combined protocol to maximize detection of synchronous breast lesions. 10

Risk of Malignancy in Biopsied Axillary Nodes

• In patients without a prior history of breast cancer, only ≈ 7 % of abnormal‑appearing axillary nodes that undergo biopsy are malignant; the probability rises with increasing age. The ACR highlights this age‑related risk gradient. 9

Ultrasound Features that Prompt Core Needle Biopsy

• Short‑axis diameter > 1 cm – nodes meeting this size criterion should be sampled with ultrasound‑guided core needle biopsy. 11
• Cortical thickness > 0.3 cm – this measurement also mandates core biopsy according to ACR guidance. 11
• Loss of the fatty hilum – the absence of a fatty hilum carries the highest positive predictive value (90–93 %) for malignancy and therefore requires core needle biopsy. 11

Evidence strength: The ACR notes that these morphologic thresholds are derived from retrospective cohort analyses demonstrating high predictive values, though exact grading (e.g., Level II) is not specified in the source.

Limitations of Imaging Modalities

• Axillary ultrasound alone has limited negative predictive value, with reported sensitivity ranging from 26 % to 94 % and specificity from 53 % to 98 %. The ACR cautions against relying on a negative ultrasound to exclude cancer. 11
• Mammography without adjunctive ultrasound exhibits a high false‑negative rate for detecting axillary lymphadenopathy. The ACR advises combined imaging to improve detection. 11

Role of Advanced Imaging When Initial Work‑up Is Inconclusive

• FDG‑PET/CT is not recommended as a first‑line study for an axillary mass of unknown cause because of its low yield in identifying occult primary malignancy before tissue confirmation. The ACR advises reserving PET/CT for later staging when malignancy is already established. 9
• Chest CT may be useful when there is suspicion of chest‑wall invasion or when systemic diseases such as lymphoma are in the differential, to assess additional thoracic lymphadenopathy and local extension. The ACR includes CT as a secondary imaging option in these scenarios. 12